TeGenero AG
http://www.tegenero.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TeGenero AG
2016 – The Pharma Year In Review
As we enter a new year, Scrip takes a look at the five biggest themes that got the most hits from our readers over the last 12 months.
Surviving a Scandal: How to Expect the Unexpected
By their very nature, crises are unexpected, which makes the planning and management involved all the more important when defining a company strategy in the modern age of 24-hour social media.
Doing the right thing in clinical trials
A newspaper has launched a campaign in the UK to review the way that clinical trials are carried out in adolescents. It follows the death of a 17-year-old girl with Ewing’s sarcoma who was rejected for inclusion in a clinical trial of an experimental anticancer product on the grounds that she was too young: the inclusion criteria specified a minimum age of 18 years. The case has become something of a cause célèbre, as the girl was only weeks away from her 18th birthday.
Stockwatch: The metamorphosys of German Biotech
The €70 million first close of Germany's Wellington Partners fourth fund on 19 September was widely lauded as a sign of recovery of the European venture capital market (scripintelligence.com, 19 September 2012). But a more tangible indication of value was the clinical progress announced in the same week by publicly-quoted German biotech Morphosys.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice